Patents Assigned to Idun Pharmaceuticals, Inc.
-
Patent number: 7183260Abstract: This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.Type: GrantFiled: August 25, 2004Date of Patent: February 27, 2007Assignee: Idun Pharmaceuticals, Inc.Inventors: Donald S Karanewsky, Robert J Ternansky, Steven D Linton, Thang Dinh
-
Patent number: 7157430Abstract: This invention is directed to novel (substituted) acyl dipeptidyl ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.Type: GrantFiled: July 20, 2001Date of Patent: January 2, 2007Assignee: Idun Pharmaceuticals, Inc.Inventors: Donald S Karanewsky, Vincent J Kalish, Edward D Robinson, Brett R Ullman
-
Patent number: 7053056Abstract: This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.Type: GrantFiled: January 16, 2001Date of Patent: May 30, 2006Assignee: Idun Pharmaceuticals, Inc.Inventors: Donald S. Karanewsky, Robert J. Ternansky, Steven D. Linton, Thang Dinh
-
Publication number: 20060084613Abstract: This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds having the following structure: wherein A, B, R, R1, R1? p and q are as defined herein. The invention is also directed to pharmaceutical compositions containing one or more of these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.Type: ApplicationFiled: September 30, 2005Publication date: April 20, 2006Applicant: Idun Pharmaceuticals, Inc.Inventors: Robert Ternansky, Patricia Gladstone, Kevin Tomaselli, Bin Chao, Steven Linton
-
Patent number: 6969703Abstract: This invention is directed to novel sulfonimide (substituted)acyl dipeptidyl ICE/ced-3 family inhibitor compounds having the following structure: wherein A, B, X, R, R1, R2, n, q, and r are as defined herein. The invention is also directed to pharmaceutical compositions containing these compounds, as well as the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.Type: GrantFiled: December 17, 2002Date of Patent: November 29, 2005Assignee: Idun Pharmaceuticals, Inc.Inventors: Robert J. Ternansky, Patricia L. Gladstone, Kevin J. Tomaselli
-
Patent number: 6897296Abstract: The invention provides an isolated gene encoding Mch4 or an isolated gene encoding Mch5 as well as functional fragments thereof. Also provided are isolated nucleic acid sequences encoding Mch4 or Mch5 or functional fragment thereof. The gene or nucleic acid sequences can be single or double stranded nucleic acids corresponding to coding or non-coding strands of the Mch4 or Mch5 nucleotide sequences. Also provided are genes and nucleic acids encoding functional fragments such as the FADD-like domains Mch4A, Mch4B, Mch5A and Mch5B. Isolated Mch4 or Mch5 polypeptides or functional fragments thereof including the FADD-like domains Mch4A, Mch4B, Mch5A and Mch5B are also provided.Type: GrantFiled: September 22, 2003Date of Patent: May 24, 2005Assignees: IDUN Pharmaceuticals, Inc., Thomas Jefferson UniversityInventors: Emad S. Alnemri, Teresa Fernandes-Alnemri, Gerald Litwack, Robert Armstrong, Kevin Tomaselli
-
Publication number: 20050065093Abstract: This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds having the following structure: wherein A, B, R, R1, R1? p and q are as defined herein. The invention is also directed to pharmaceutical compositions containing one or more of these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.Type: ApplicationFiled: August 10, 2004Publication date: March 24, 2005Applicant: Idun Pharmaceuticals, Inc.Inventors: Robert Ternansky, Patricia Gladstone, Kevin Tomaselli, Bin Chao, Steven Linton
-
Publication number: 20050020504Abstract: This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.Type: ApplicationFiled: August 25, 2004Publication date: January 27, 2005Applicant: Idun Pharmaceuticals, Inc.Inventors: Donald Karanewsky, Robert Ternansky, Steven Linton, Thang Dinh
-
Patent number: 6824991Abstract: The invention provides an isolated gene and an isolated nucleic acid sequence encoding human Bad and functional fragments thereof. Also provided is an isolated human Bad polypeptide and functional fragments thereof. Methods of identifying human Bad binding partners and methods of screening for compounds which interfere with the association of human Bad interacting polypeptides with human Bad are also provided. Finally, methods for decreasing or increasing the viability of a cell are provided as well.Type: GrantFiled: August 3, 2001Date of Patent: November 30, 2004Assignee: IDUN Pharmaceuticals Inc.Inventors: William A. Horne, Tilman Oltersdorf
-
Patent number: 6790989Abstract: This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds having the following structure: wherein A, B, R, R1, R1′ p and q are as defined herein. The invention is also directed to pharmaceutical compositions containing one or more of these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmnune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.Type: GrantFiled: July 18, 2001Date of Patent: September 14, 2004Assignee: Idun Pharmaceuticals, Inc.Inventors: Robert J. Ternansky, Patricia L. Gladstone, Kevin J. Tomaselli, Bin Chao, Steven D. Linton
-
Patent number: 6762045Abstract: Provided are isolated nucleic acids encoding a novel membrane derived caspase-3 and polypeptides expressed therefrom. In one embodiment, the nucleic acid expression vectors that produce membrane derived caspase-3 polypeptide may be introduced into host cells as a gene delivery vehicle. In other embodiments, methods are provided for treating pathological disorders caused by altered apoptosis, such as autoimmune disease, cancer, viral infections, and bacterial infections. Another aspect of the invention is the use of the isolated nucleic acid encoding membrane derived caspase-3 and polypeptides expressed therefrom as a means for promoting or inhibiting programmed cell death.Type: GrantFiled: March 20, 2002Date of Patent: July 13, 2004Assignee: Idun Pharmaceuticals, Inc.Inventors: Joseph F. Krebs, Anupama Srinivasan, Lawrence C. Fritz, Joe C. Wu
-
Patent number: 6730779Abstract: The invention provides an isolated gene encoding Mch4 or an isolated gene encoding Mch5 as well as functional fragments thereof. Also provided are isolated nucleic acid sequences encoding Mch4 or Mch5 or functional fragment thereof. The gene or nucleic acid sequences can be single or double stranded nucleic acids corresponding to coding or non-coding strands of the Mch4 or Mch5 nucleotide sequences. Also provided are genes and nucleic acids encoding functional fragments such as the FADD-like domains Mch4A, Mch4B, Mch5A and Mch5B. Isolated Mch4 or Mch5 polypeptides or functional fragments thereof including the FADD-like domains Mch4A, Mch4B, Mch5A and Mch5B are also provided.Type: GrantFiled: September 10, 2001Date of Patent: May 4, 2004Assignees: IDUN Pharmaceuticals, Inc., Thomas Jefferson UniversityInventors: Emad S. Alnemri, Teresa Fernandes-Alnemri, Gerald Litwack, Robert Armstrong, Kevin Tomaselli
-
Patent number: 6716960Abstract: The invention provides an isolated gene encoding Mch3, or functional fragment thereof. Also provided is an isolated nucleic acid sequence encoding Mch3 or functional fragment thereof. The gene or nucleic acid sequence can be single or double stranded nucleic acids corresponding to coding or non-coding strands of the Mch3 nucleotide sequence. An isolated Mch3 polypeptide or functional fragment thereof is also provided.Type: GrantFiled: January 2, 2003Date of Patent: April 6, 2004Assignees: Idun Pharmaceuticals, Inc., Thomas Jefferson UniversityInventors: Emad S. Alnemri, Teresa Fernandes-Alnemri, Gerald Litwack, Robert Armstrong, Kevin Tomaselli
-
Publication number: 20040058850Abstract: The present invention provides methods and compositions for treating infectious disease or suppressing inflammation associated therewith or ameliorating symptoms thereof by the suppression of the activity of a member of the interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family of proteases. Also provided are compositions useful for these purposes. Exemplary compounds useful in the methods of the invention are provided herein.Type: ApplicationFiled: September 2, 2003Publication date: March 25, 2004Applicant: Idun Pharmaceuticals, Inc.Inventors: Lawrence C. Fritz, Kevin J. Tomaselli, Donald S. Karanewsky, Steven D. Linton, Xu Bai
-
Patent number: 6693096Abstract: The present invention provides methods and compositions for preventing and treating inflammation-associated disorders or ameliorating symptoms thereof by the suppression of the activity of a member of the interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family of proteases. Also provided are compositions useful for these purposes. Exemplary compounds useful in the methods of the invention are provided herein.Type: GrantFiled: July 29, 2002Date of Patent: February 17, 2004Assignee: IDUN Pharmaceuticals, Inc.Inventors: Lawrence C. Fritz, Kevin J. Tomaselli, Donald S. Karanewsky, Steven D. Linton, Xu Bai
-
Patent number: 6686459Abstract: The invention provides an isolated gene encoding Mch3, or functional fragment thereof. Also provided is an isolated nucleic acid sequence encoding Mch3 or functional fragment thereof. The gene or nucleic acid sequence can be single or double stranded nucleic acids corresponding to coding or non-coding strands of the Mch3 nucleotide sequence. An isolated Mch3 polypeptide or functional fragment thereof is also provided.Type: GrantFiled: September 29, 1998Date of Patent: February 3, 2004Assignees: IDUN Pharmaceuticals, Inc., Thomas Jefferson UniversityInventors: Emad S. Alnemri, Teresa Fernandes-Alnemri, Gerald Litwack, Robert Armstrong, Kevin Tomaselli
-
Publication number: 20030232788Abstract: This invention is directed to novel (substituted)acyl dipeptidyl ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.Type: ApplicationFiled: February 7, 2003Publication date: December 18, 2003Applicant: Idun Pharmaceuticals, Inc.Inventors: Donald S. Karanewsky, Vincent J. Kalish, Edward D. Robinson, Brett R. Ullman
-
Publication number: 20030199454Abstract: This invention is directed to novel sulfonimide (substituted)acyl dipeptidyl ICE/ced-3 family inhibitor compounds having the following structure: 1Type: ApplicationFiled: December 17, 2002Publication date: October 23, 2003Applicant: IDUN Pharmaceuticals, Inc.Inventors: Robert J. Ternansky, Patricia L. Gladstone, Kevin J. Tomaselli
-
Publication number: 20030186842Abstract: The present invention provides methods and compositions for treating infectious disease or suppressing inflammation associated therewith or ameliorating symptoms thereof by the suppression of the activity of a member of the interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family of proteases. Also provided are compositions useful for these purposes. Exemplary compounds useful in the methods of the invention are provided herein.Type: ApplicationFiled: July 29, 2002Publication date: October 2, 2003Applicant: Idun Pharmaceuticals, Inc.Inventors: Lawrence C. Fritz, Kevin J. Tomaselli, Donald S. Karanewsky, Steven D. Linton, Xu Bai
-
Patent number: 6610683Abstract: The present invention provides methods and compositions for treating infectious disease or suppressing inflammation associated therewith or ameliorating symptoms thereof by the suppression of the activity of a member of the interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family of proteases. Also provided are compositions useful for these purposes. Exemplary compounds useful in the methods of the invention are provided herein.Type: GrantFiled: November 13, 2001Date of Patent: August 26, 2003Assignee: IDUN Pharmaceuticals, Inc.Inventors: Lawrence C. Fritz, Kevin J. Tomaselli, Donald S. Karanewsky, Steven D. Linton, Xu Bai